
About LifeMine Therapeutics
LifeMine Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2016 by Gregory Verdine and Weiqing Zhou. Developer of novel drugs from fungi via genome mining and recombinant overexpression. LifeMine Therapeutics has raised $826.07 million across 9 funding rounds from investors including Fidelity Investments, Arch Venture Partners and GSK. The company has 85 employees. Its chief executive, as recorded, is Gregory Verdine. LifeMine Therapeutics offers products and services including LIFE-001 and Top-Down Drug Discovery Engine. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Amyris, Avidity Biosciences and AskBio; 3 of its 3 listed competitors have raised funding.
Company details
LifeMine Therapeutics was founded in 2016 in Cambridge, Massachusetts, United States. Operations focus on the biotech sector, where fungal genomes are mined and recombinant overexpression is applied to identify new molecules. These compounds are targeted for treating difficult human diseases through unconventional biological pathways. The approach involves extensive exploration of the fungal biosphere to uncover potential therapeutics.
- Headquarters Cambridge, United States
- Employees 85
- Founders Gregory Verdine, Weiqing Zhou
- SectorsHealthcare
- Website lifeminetx.com
- Social LinkedIn
- Legal Name Lifemine Therapeutics
- Total Equity Funding$826.07M (USD)
in 9 rounds
- Latest Funding Round$188M (USD), Series E
Aug 2026
- InvestorsFidelity Investments
& 16 more
- Employee Count85
Products & Services of LifeMine Therapeutics
LifeMine Therapeutics offers a comprehensive portfolio of products and services, including LIFE-001 and Top-Down Drug Discovery Engine.
Precision-engineered inhibitor for treating immune-mediated diseases and transplant rejection.
Data-driven system for uncovering novel precision medicines from fungal sources.
Funding Insights of LifeMine Therapeutics
LifeMine Therapeutics has successfully raised a total of $826.07M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $188 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $826.07M
- Total Rounds 9
- Last Round Series E β $188M
- First Round $5M
(Sep 2016)
- Investors Count 17
All 9 funding rounds of LifeMine Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | $75M | Series D | β | β | |
| Aug 2026 | $188M | Series E | β | β | |
| Aug 2026 | $75M | Series D | β | β | |
| Aug 2026 | $188M | Series E | β | β | |
| Mar 2022 | $175M | Series C | β | Fidelity Investments | |
| Jan 2021 | $50M | Series B | β | Rick Klausner, Milky Way Cap | |
| Mar 2019 | $70.07M | Series A | β | 6 Dimensions Capital | |
| Sep 2016 | $5M | Series A | β | β | β |
| Sep 2016 | Debt – Conventional | β | β | β |
17 investors in total: 16 institutional and 1 angel.
Investors in LifeMine Therapeutics
LifeMine Therapeutics has secured backing from 17 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Fidelity Investments, Arch Venture Partners and GSK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
| 3wpcap.com | ||||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Seed and early-stage therapeutics companies are invested in by MRLV. | mrlv.com | Cambridge, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
| milkywaycap.com | ||||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Life-Sciences focused early and growth stage VC firm funding companies in China & the US | 6dimensionscapital.com | Pudong, China | ||
Boyu Capital is recognized as a leading alternative asset management firm. | boyucapital.com | Hong Kong, China | ||
Early stage investments focused VC firm | acks.com |
Investor details for LifeMine Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of LifeMine Therapeutics
13 people are tracked at LifeMine Therapeutics (7 in leadership, 5 in board & advisors, 1 in team); the tracked headcount is 85.
| Name | Role | Group |
|---|---|---|
Gregory Verdine | Co-Founder & CEO | Leadership |
Weiqing Zhou | Co-Founder & COO | Leadership |
Michael Dube | Head Of Facilities & Lab Operations | Leadership |
Mary Alvarado | Senior Administrative Business Partner | Leadership |
David Surguladze | Vp, Head Of Non-clinical Development | Leadership |
Megan Norman | Associate Director Of Clinical Operations | Leadership |
Jenny Shu | Senior Director Biology Immunology | Leadership |
Krishna Yeshwant | Board Member | Board & advisors |
Edward Hu | Board Member | Board & advisors |
William G. Kaelin Jr. | Board Member | Board & advisors |
Jennifer A. Jarrett | Board Member | Board & advisors |
Richard Klausner | Chairman | Board & advisors |
Karen Guarco | SVP, Finance & Research Operations | Team |
Complete people profiles for LifeMine Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of LifeMine Therapeutics
3 dated milestones of LifeMine Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded LifeMine Therapeutics is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series E, of $188.0M.
Competitors of LifeMine Therapeutics
LifeMine Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Amyris, Avidity Biosciences and AskBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. |
Detailed competitors of LifeMine Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of LifeMine Therapeutics
The website of LifeMine Therapeutics (lifeminetx.com) receives about 3.5K visits a month.
- Monthly visits3.5K
▲ 55.7% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as LifeMine Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lifemine Therapeutics
Complete news archive for LifeMine Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LifeMine Therapeutics
LifeMine Therapeutics was founded in 2016.
LifeMine Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Gregory Verdine is the CEO of LifeMine Therapeutics, as recorded in our data. They have also founded this company.
LifeMine Therapeutics is a funded company, having raised a total of $826.07M across 9 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Sep 2016.
LifeMine Therapeutics has 85 employees.
LifeMine Therapeutics was founded in 2016 in Cambridge, Massachusetts, United States. Operations focus on the biotech sector, where fungal genomes are mined and recombinant overexpression is applied to identify new molecules. These compounds are targeted for treating difficult human diseases through unconventional biological pathways. The approach involves extensive exploration of the fungal biosphere to uncover potential therapeutics.
LifeMine Therapeutics's top competitors include Avidity Biosciences, Amyris and AskBio.
LifeMine Therapeutics offers LIFE-001 and Top-Down Drug Discovery Engine.
LifeMine Therapeutics has 17 investors. Key investors include Fidelity Investments, Arch Venture Partners, GSK, Invus, and 3W Partners.
LifeMine Therapeutics operates through Lifemine Therapeutics.
